Department of Human Health, Division of Ecosystems and Immunity, Center Scientific of Monaco, Monaco MC98000, Monaco.
Center Scientific of Monaco, Monaco MC98000, Monaco.
World J Gastroenterol. 2019 May 14;25(18):2188-2203. doi: 10.3748/wjg.v25.i18.2188.
The yeast CNCM I-745 is one of the probiotics recommended for the prevention of antibiotic-associated diarrhea. Studies conducted and demonstrated that in the case of infectious diseases there are two potential sites of action of CNCM I-745: (1) An action on enteropathogenic microorganisms (adhesion of bacteria and their elimination or an effect on their virulence factors: Toxins, lipopolysaccharide, .); and (2) a direct action on the intestinal mucosa (trophic effects, effects on epithelial reconstitution, anti-secretory effects, anti-inflammatory, immunomodulators). Oral administration of CNCM I-745 to healthy subjects does not alter their microbiota. However, in the case of diseases associated with the use of antibiotics or chronic diarrhea, CNCM I-745 can restore the intestinal microbiota faster. The interaction of CNCM I-745 with the innate immune system have been recently demonstrated thus opening up a new therapeutic potential of this yeast in the case of diseases associated with intestinal infections but also other pathologies associated with dysbiosis such as inflammatory diseases.
酵母 CNCM I-745 是推荐用于预防抗生素相关性腹泻的益生菌之一。研究表明,在感染性疾病的情况下,CNCM I-745 有两个潜在的作用部位:(1)对肠致病性微生物的作用(细菌的黏附和消除或对其毒力因子的影响:毒素、脂多糖等);(2)对肠道黏膜的直接作用(营养作用、对上皮重建的影响、抗分泌作用、抗炎作用、免疫调节剂)。口服 CNCM I-745 对健康受试者的微生物群没有改变。然而,在与抗生素使用或慢性腹泻相关的疾病中,CNCM I-745 可以更快地恢复肠道微生物群。最近已经证明了 CNCM I-745 与先天免疫系统的相互作用,从而为这种酵母在与肠道感染相关的疾病以及其他与微生态失调相关的病理,如炎症性疾病,开辟了新的治疗潜力。